CYP26B1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2896779	0.77	8/20
SCHEMBL4365965	0.55	8/20
SCHEMBL2095481	0.54	8/20
SCHEMBL4527394	0.51	8/20
SCHEMBL3176733	0.51	8/20
SCHEMBL694638	0.50	8/20
SCHEMBL1616186	0.50	8/20
SCHEMBL2312146	0.50	8/20
SCHEMBL3546404	0.50	8/20
SCHEMBL3454051	1.00	7/20
SCHEMBL4440994	0.51	7/20
SCHEMBL1616121	0.69	6/20
SCHEMBL1132946	0.65	6/20
SCHEMBL2897524	0.53	6/20
SCHEMBL2808583	1.00	5/20
SCHEMBL1616078	0.69	5/20
SCHEMBL2433471	0.67	5/20
SCHEMBL727916	0.64	5/20
SCHEMBL4001259	0.60	5/20
SCHEMBL4001262	0.60	5/20

Clinical trials — most relevant to CYP26B1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Effect of Genetics on Metabolism of Efavirenz	PHASE4	COMPLETED
Pharmacogenetics of Nicotine Addiction Treatment	PHASE3	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis	PHASE2	ACTIVE_NOT_RECRUITING
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma	PHASE1	COMPLETED
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH	PHASE1	UNKNOWN
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients	PHASE1	COMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics	nan	COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
CYP2B6 Polymorphisms in Methadone Disposition	nan	COMPLETED
Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva	nan	COMPLETED
EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients	nan	COMPLETED
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk	nan	COMPLETED
Pharmacogenetics of Bupropion Metabolism	nan	COMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease	nan	COMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
Mutation Analysis of 17α-Hydroxylase	nan	UNKNOWN
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors	nan	COMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
Pharmacogenomic Profiling of Pediatric Patients	nan	COMPLETED
Connecting Breath and Mind for CYP With Long COVID	nan	UNKNOWN
Development of PK/PD Model for Individualized Propofol Dosing	nan	COMPLETED
CYP2B6 Polymorphisms in Ketamine	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP26B1 binder may also engage these)

Protein	Name	Similarity
E1BHJ4	—	1.000	E1BHJ4 →
G3V7X8	—	1.000	G3V7X8 →
Q08D50	—	1.000	Q08D50 →
Q811W2	—	1.000	Q811W2 →
Q6EIG3	—	0.998	Q6EIG3 →
O93323	—	0.996	O93323 →
P79739	—	0.990	P79739 →
Q50EK5	—	0.990	Q50EK5 →
F1RE08	—	0.990	F1RE08 →
A0A9Y1LLN2	—	0.989	A0A9Y1LLN2 →
Q6JD68	—	0.989	Q6JD68 →
Q84KI1	—	0.989	Q84KI1 →
Q9FMA5	—	0.988	Q9FMA5 →
Q940V4	—	0.987	Q940V4 →
Q9AXM6	—	0.987	Q9AXM6 →
Q50EK0	—	0.987	Q50EK0 →
A0A5B8ND22	—	0.987	A0A5B8ND22 →
Q60991	—	0.987	Q60991 →
A0A067E1K2	—	0.987	A0A067E1K2 →
Q50EK1	—	0.987	Q50EK1 →
H2DH16	—	0.987	H2DH16 →
B2RXA7	—	0.987	B2RXA7 →
Q8W4T9	—	0.986	Q8W4T9 →
Q50LE0	—	0.986	Q50LE0 →
I1GQE7	—	0.986	I1GQE7 →
O23051	—	0.986	O23051 →
Q50EK6	—	0.986	Q50EK6 →
Q9PUB4	—	0.985	Q9PUB4 →
P0DXH4	—	0.985	P0DXH4 →
Q6JTJ0	—	0.985	Q6JTJ0 →